摘要
目的 观察卡维地洛与拉贝洛尔治疗轻中度原发性高血压的临床疗效及安全性.方法 选择轻中度原发性高血压患者107例,随机分为卡维地洛组（54例）和拉贝洛尔组（53例）,分别给予卡维地洛和拉贝洛尔口服治疗24周.观察2组患者血压、心率、血糖和血脂变化情况及不良反应.结果 2组在治疗2周时血压均有所下降,在治疗6～8周末下降最明显,并维持至24周.卡维地洛组和拉贝洛尔组降压总有效率分别为83%和78%.治疗后卡维地洛组患者血糖、血脂无明显变化,拉贝洛尔组患者的高密度脂蛋白胆固醇及低密度脂蛋白胆固醇均显著增高.2组均无严重不良事件发生.结论 卡维地洛对轻中度原发性高血压降压效果显著,是一种安全有效的抗高血压药物,耐受性及安全性好.
Objective It is to observe the clinical efficacy and the safety of carvedilol and labetalol for mild to moderate essential hypertension. Methods 107 patients with essential hypertension were chosen and randomly divided into two groups： c arvedilol group （54 cases） and labetalol group（53 cases） who took carvediiol tablet per day or bisoprolol tablet per day for 24 weeks. The changes of blood pressure, heart rate and blood fat and sugar in the two groups and the adverse effect were observed. Results The clinic blood pressure of the two groups decreased at the end of two weeks of treatment, and the decrease showed most significant at the end of 6 - 8 weeks of treatment and maintained the same level to the end of 24 week. The total effective rates of decreasing blood pressure of carvedilol therapy and hisoprolol therapy was 83% and 78% respectively. There was no difference in the levels of blood glucose and blood fat between before and after treatment in carvedilol group, while in labetalol group the levels of high density lipoprotein cholesterol and low density lipoprotein cholesterol obviously increased after treatment. The was no severe adverse effect in the two groups. Conclusions Carvedilol was an effective, tolerable and safe anti-hypertension drug for mild to moderate essential hypertension.
出处
《现代中西医结合杂志》
CAS
2010年第31期3370-3371,3420,共3页
Modern Journal of Integrated Traditional Chinese and Western Medicine
